What we do
At Polpharma Biologics we are focused on developing the next generation of biosimilars to improve patient access and reduce health care costs.
Our pipeline is continuously growing and our late stage products are nearing the market. We look to partner with some of the worlds largest biotech so our biosimilars can reach those that need them.
6+
biologics in the pipeline
3
Development & manufacturing facilities
Bioreactor production capacity
People employed
Polish scientists returned from abroad
We care
our driving value for what we do
Our partnerships
We partner with some of the world’s largest biotechnology and pharmaceutical companies to advance and market our biosimilars. It is through their extensive supply network that we can reach as many people as possible that need our biosimilars.
From Scientific Insight to Patient Impact
Advancing biosimilars with velocity and purpose to deliver meaningful impact for patients worldwide.
Our globally connected model is built on a focused internal core and a strong external network. We retain critical capabilities in-house while partnering with trusted CDMOs, clinical providers, and commercialization partners to deliver at scale.
By integrating scientific, clinical, regulatory, and technical leadership, we guide biosimilars from early development through commercial production – and sustain their value throughout the product lifecycle.
Our Capabilities
End-to-end lifecycle leadership
Overseeing programs from cell line to commercial supply
Strategic development oversight
Aligning scientific, regulatory, and clinical pathways
Commercial production readiness
Building scalable, supply-secure manufacturing strategies
Device and combination product development
Supporting safe and effective patient use
Advanced cell line, analytical, and CMC expertise
Establishing strong technical foundations
Comprehensive leadership from development through commercial production – across the full lifecycle.
How We Deliver Impact
Lead with ownership
Driving programs with lifecycle accountability
Move with velocity
Enabling focused decisions and efficient pathways
Prioritize impact
Advancing therapies that expand patient access
Collaborate globally
Partnering strategically while maintaining oversight
Execute with discipline
Balancing speed, quality, cost, and reliability
Because patients depend not only on innovation – but on therapies that remain available and trusted over time.
Focused at the core. Connected for scale. Accountable across the lifecycle.
Our operating model combines a focused internal core with a strong external network. We retain critical capabilities in-house while partnering with trusted providers to deliver at scale.
By aligning scientific, clinical, regulatory, technical, and commercial perspectives early, we reduce complexity, strengthen decision-making, and support reliable long-term supply.
How We Are Built
Focused internal core
Experienced leadership providing strategic direction and oversight
Critical capabilities retained in-house
Ensuring consistency and quality
Best-in-class external network
E xtending capabilities within clear governance
Integrated across the lifecycle
Aligning development through commercialization
Designed for velocity and resilience
Enabling efficient execution and sustained program viability
The result is an agile, scalable model built for long-term patient access.